Cetera Investment Advisers Boosts Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Cetera Investment Advisers lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 107,789 shares of the medical research company’s stock after buying an additional 5,593 shares during the period. Cetera Investment Advisers’ holdings in Thermo Fisher Scientific were worth $52,982,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of TMO. High Note Wealth LLC boosted its position in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. Swiss RE Ltd. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. Olistico Wealth LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Legacy Wealth Managment LLC ID grew its stake in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the period. Finally, Birchwood Financial Partners Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $29,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $567.34 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm’s 50-day moving average price is $494.01 and its 200-day moving average price is $513.46. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a market cap of $210.83 billion, a PE ratio of 30.52, a PEG ratio of 2.51 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.08 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. DZ Bank started coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 target price on the stock. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $613.05.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher beat Q2 expectations on both earnings and revenue, reporting $6.03 in adjusted EPS versus $5.71 expected and $11.99 billion in revenue versus $11.71 billion expected, with organic revenue up 5% year over year. Reuters article
• Positive Sentiment: The company raised its FY 2026 guidance, signaling management’s confidence that customer demand recovery should continue and that the stronger quarter was not a one-off. Business Wire article
• Positive Sentiment: Analysts pointed to broad-based improvement in life sciences and biopharma activity, plus price target upgrades, as additional support for the stock’s rally. Yahoo Finance article
• Neutral Sentiment: Thermo Fisher also launched InstaFlux for food microbiology labs, a product announcement that may help long-term workflow adoption but is not likely the main driver of the stock move today. Business Wire article
• Neutral Sentiment: One analyst note suggested the strong quarter may not materially change the second-half outlook, indicating some caution after the earnings beat. Yahoo Finance article

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.